NanoMab Presents at SNMMI

Date: June 24th, 2019

NanoMab Presents at SNMMI

Anaheim, California, US, June 24th, 2019. Gitasha Chand, clinical research director of NanoMab presented NanoMab’s FIH data of ^99mTc-NM-01 at the annual meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI).

^99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole body assessment of PD-L1 expression in patients before or during immuno-oncology treatment

Also see link: Early phase I study of a 99m Tc labeled anti-PD-L1 sdAb in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer